Security
InspireMD, Inc · NSPR.WS.B
NSPR.WS.BNYSE_AMERICANWarrantHistorical · closed Jun 7, 2021CIK 1433607Updated Nov 13, 2026
Name history
Saguaro Resources, Inc. · through Apr 1, 2011
Current security for this SEC filerNSPR · NASDAQ
NSPR.WS.B price & chart
Historical security
This listing closed Jun 7, 2021. Live provider charts are shown only for current listings.
Current security: NSPR
About the company
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
In the news
No coverage from other publishers is available.
Recent filings
424B5 filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
4 filing
Show 5 more recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 78,472,000Source | 50,481,000Source | 44,641,000Source | 33,342,000Source | 55,659,000Source | 56,471,000Source | 38,672,000Source | 42,028,000Source | 69,404,000Source | 46,807,000Source | 47,643,000Source | 24,653,000Source |
| Property, Plant and Equipment, NetUSD | 3,403,000Source | 1,946,000Source | 3,858,000Source | 3,101,000Source | 1,595,000Source | 3,651,000Source | 2,736,000Source | 1,186,000Source | 3,584,000Source | 2,371,000Source | 1,060,000Source | 917,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 63,403,000Source | 15,818,000Source | 15,149,000Source | 11,509,000Source | 28,385,000Source | 11,362,000Source | 12,383,000Source | 9,389,000Source | 8,939,000Source | 18,916,000Source | 9,640,000Source | 4,632,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,961,000Source | 1,530,000Source | 1,816,000Source | 1,592,000Source | 1,307,000Source | 2,381,000Source | 1,580,000Source | 1,187,000Source | 2,168,000Source | 1,572,000Source | 1,804,000Source | 1,034,000Source |
| Inventory, NetUSD | 3,607,000Source | 2,445,000Source | 2,701,000Source | 3,054,000Source | 2,206,000Source | 3,036,000Source | 2,822,000Source | 2,360,000Source | 3,396,000Source | 2,570,000Source | 2,106,000Source | 1,621,000Source |
| Assets, CurrentUSD | 70,391,000Source | 46,394,000Source | 36,628,000Source | 25,463,000Source | 51,843,000Source | 48,594,000Source | 32,144,000Source | 38,511,000Source | 61,471,000Source | 40,521,000Source | 44,159,000Source | 21,326,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,915,000Source | 1,145,000Source | 2,428,000Source | 692,000Source | 1,257,000Source | 2,595,000Source | 2,225,000Source | 1,366,000Source | 2,758,000Source | 2,360,000Source | 1,473,000Source | 1,554,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 14,358,000Source | 9,130,000Source | 13,130,000Source | 13,099,000Source | 8,896,000Source | 12,854,000Source | 10,327,000Source | 6,941,000Source | 14,203,000Source | 10,721,000Source | 8,142,000Source | 7,260,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 5,000Source | 3,000Source | 3,000Source | 4,000Source | 3,000Source | 2,000Source | 4,000Source | 3,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 354,641,000Source | 285,680,000Source | 361,811,000Source | 298,063,000Source | 283,202,000Source | 359,594,000Source | 293,014,000Source | 263,618,000Source | 357,489,000Source | 289,589,000Source | 261,000,000Source | 218,977,000Source |
| Retained Earnings (Accumulated Deficit)USD | -290,531,000Source | -244,332,000Source | -330,305,000Source | -277,823,000Source | -236,442,000Source | -315,981,000Source | -264,672,000Source | -228,533,000Source | -302,292,000Source | -253,506,000Source | -221,501,000Source | -201,585,000Source |
| Stockholders' Equity Attributable to ParentUSD | 64,114,000Source | 41,351,000Source | 31,511,000Source | 20,243,000Source | 46,763,000Source | 43,617,000Source | 28,345,000Source | 35,087,000Source | 55,201,000Source | 36,086,000Source | 39,501,000Source | 17,393,000Source |
| Liabilities and EquityUSD | 78,472,000Source | 50,481,000Source | 44,641,000Source | 33,342,000Source | 55,659,000Source | 56,471,000Source | 38,672,000Source | 42,028,000Source | 69,404,000Source | 46,807,000Source | 47,643,000Source | 24,653,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,816,000Source | 7,265,000Source | 9,646,000Source | 9,068,000Source | 6,965,000Source | 9,443,000Source | 7,367,000Source | 4,877,000Source | 10,712,000Source | 7,678,000Source | 6,020,000Source | 5,070,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | 1,066,000Source | 542,000Source | 557,000Source | 419,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,367,000Source | 682,000Source | 1,969,000Source | 2,507,000Source | 786,000Source | 2,042,000Source | 1,639,000Source | 914,000Source | 2,224,000Source | 1,796,000Source | 1,038,000Source | 1,195,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 735,000Source | 1,437,000Source | 1,016,000Source | 1,016,000Source | 1,149,000Source | 1,146,000Source | 821,000Source | 1,101,000Source | 1,545,000Source | 1,325,000Source | 1,115,000Source | 554,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,105,000Source | 2,729,000Source | 12,332,000Source | 10,138,000Source | 4,490,000Source | 2,352,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 213,000Source | 8,000Source | 596,000Source | -232,000Source | 770,000Source | -190,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -360,000Source | 252,000Source | 826,000Source | 464,000Source | 485,000Source | 478,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,337,000Source | -8,792,000Source | -35,103,000Source | -21,868,000Source | -16,376,000Source | -15,542,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 14,779,000Source | 1,702,000Source | -30,560,000Source | 12,641,000Source | -16,092,000Source | 8,441,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 194,000Source | 359,000Source | 1,662,000Source | 1,402,000Source | 381,000Source | 473,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 506,000Source | 55,569,000Source | 18,452,000Source | 37,534,000Source | -140,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 2,423,000Source | -6,533,000Source | -9,977,000Source | 9,276,000Source | 5,008,000Source | -7,372,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 12,332,000Source | 10,138,000Source | 4,490,000Source | 2,352,000Source |
| DepreciationUSD | — | — | — | — | — | — | 149,000Source | 98,000Source | 476,000Source | 280,000Source | 232,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 14,000Source | — | 6,000Source | — |
| General and Administrative ExpenseUSD | — | — | 5,888,000Source | 3,489,000Source | 4,155,000Source | 5,326,000Source | 4,722,000Source | 4,943,000Source | 20,707,000Source | 15,306,000Source | 11,104,000Source | 8,356,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 63,000Source | 59,000Source | 65,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,708,000Source | -7,890,000Source | -14,324,000Source | -13,151,000Source | -13,689,000Source | -11,166,000Source | -48,786,000Source | -32,005,000Source | -19,916,000Source | -18,491,000Source |
| Nonoperating Income (Expense)USD | — | — | 343,000Source | 572,000Source | 121,000Source | -132,000Source | 289,000Source | 294,000Source | 891,000Source | 1,557,000Source | 1,292,000Source | 250,000Source |
| Operating ExpensesUSD | — | — | 13,915,000Source | 8,876,000Source | 13,671,000Source | 13,332,000Source | 14,665,000Source | 11,752,000Source | 52,263,000Source | 35,009,000Source | 22,950,000Source | 19,830,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 19,000,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 506,000Source | 1,000,000Source | 1,000,000Source | — | — |
| Inventory Write-down | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,523,000Source | 1,810,000Source | 1,771,000Source | 1,778,000Source | 3,398,000Source | 1,529,000Source | 8,979,000Source | 7,009,000Source | 6,205,000Source | 5,171,000Source |
| Cost of RevenueUSD | — | — | 1,659,000Source | 1,396,000Source | 2,545,000Source | 1,465,000Source | 2,711,000Source | 1,237,000Source | 6,330,000Source | 5,503,000Source | 4,398,000Source | 4,054,000Source |
| Operating Income (Loss)USD | — | — | -13,051,000Source | -8,462,000Source | -14,445,000Source | -13,019,000Source | -13,978,000Source | -11,460,000Source | -49,614,000Source | -33,503,000Source | -21,143,000Source | -18,713,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -48,723,000Source | -31,946,000Source | -19,851,000Source | -18,463,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 63,000Source | 59,000Source | 65,000Source | 28,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,708,000Source | -7,890,000Source | -14,324,000Source | -13,151,000Source | -13,689,000Source | -11,166,000Source | -48,786,000Source | -32,005,000Source | -19,916,000Source | -18,491,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.17Source | -0.16Source | -0.17Source | -0.26Source | -0.16Source | 0.22Source | -0.76Source | -0.76Source | -0.82Source | -2.35Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.17Source | -0.16Source | -0.17Source | -0.26Source | -0.16Source | 0.22Source | -0.76Source | -0.76Source | -0.82Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 73,466,501Source | 48,369,412Source | 84,659,943Source | 51,003,900Source | 83,801,839Source | 49,993,509Source | 64,325,810Source | 41,928,360Source | 24,268,181Source | 7,871,814Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 73,466,501Source | 48,369,412Source | 84,659,943Source | 51,003,900Source | 83,801,839Source | 49,993,509Source | 64,325,810Source | 41,928,360Source | 24,268,181Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 476,000,000Source | 280,000,000Source | 232,000,000Source | 188,000Source |
| General and Administrative ExpenseUSD | — | — | 5,888,000Source | 3,489,000Source | 4,155,000Source | 5,326,000Source | 4,722,000Source | 4,943,000Source | 20,707,000Source | 15,306,000Source | 11,104,000Source | 8,356,000Source |
| Gross ProfitUSD | — | — | 864,000Source | 414,000Source | -774,000Source | 313,000Source | 687,000Source | 292,000Source | 2,649,000Source | 1,506,000Source | 1,807,000Source | 1,117,000Source |
| Nonoperating Income (Expense)USD | — | — | 343,000Source | 572,000Source | 121,000Source | -132,000Source | 289,000Source | 294,000Source | 891,000Source | 1,557,000Source | 1,292,000Source | 250,000Source |
| Operating ExpensesUSD | — | — | 13,915,000Source | 8,876,000Source | 13,671,000Source | 13,332,000Source | 14,665,000Source | 11,752,000Source | 52,263,000Source | 35,009,000Source | 22,950,000Source | 19,830,000Source |
| Other Cost of Operating RevenueUSD | — | — | 268,000Source | 187,000Source | 302,000Source | 327,000Source | 1,020,000Source | 212,000Source | 1,130,000Source | 805,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 3,635,000Source | 3,915,000Source | 4,295,000Source | 3,834,000Source | 4,763,000Source | 4,059,000Source | 15,003,000Source | 13,634,000Source | 7,981,000Source | 7,810,000Source |
| Selling and Marketing ExpenseUSD | — | — | 4,392,000Source | 1,472,000Source | 5,221,000Source | 4,172,000Source | 5,180,000Source | 2,750,000Source | 16,553,000Source | 6,069,000Source | 3,865,000Source | 3,664,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call today, November 12th, at 4:30pm ET - Miami, FL - November 12, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, toda…
Read attachment ↗ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually - - Approval supported by CGUARDIANS II pivotal trial data, which demonstrated 100% acute device success and zero death, stroke, myocardial infarction or stent thrombosis reported at 30 days - Mi…
Read attachment ↗ex99-1.htm · 4 · 2026-09-23
Exhibit 99.1 Explanation of Responses: 1. On September 18, 2026, the Reporting Person and InspireMD, Inc. (the “Company”) entered into an amendment (the “Series J Warrant Amendment”) to the Reporting Person’s Series J Common Stock Purchase Warrant (the “Original Series J Warrant”). The Series J Warrant Amendment modified the exercise price and termination date applicable to 30,625 shares underlying the Original Series J Warrant, representing approximately 50% of the 61,249 shares underlying th…
Read attachment ↗ex99-1.htm · 4 · 2026-09-23
Exhibit 99.1 Explanation of Responses: 1. On September 18, 2026, the Reporting Person and InspireMD, Inc. (the “Company”) entered into an amendment (the “Series J Warrant Amendment”) to the Reporting Person’s Series J Common Stock Purchase Warrant (the “Original Series J Warrant”). The Series J Warrant Amendment modified the exercise price and termination date applicable to 15,313 shares underlying the Original Series J Warrant, representing approximately 50% of the 30,625 shares underlying th…
Read attachment ↗ex4-1.htm · 8-K · 2026-09-21
Exhibit 4.1 SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT INSPIREMD, INC. THIS SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT (this “ Amendment ”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “ Company ”), and the holder identified on the signature page hereto (the “ Holder ”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below). WHEREAS, the Holder i…
Read attachment ↗ex4-2.htm · 8-K · 2026-09-21
Exhibit 4.2 Series K Common Stock Purchase Warrant AMENDMENT INSPIREMD, INC. THIS SERIES K COMMON STOCK PURCHASE WARRANT AMENDMENT (this “ Amendment ”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “ Company ”), and the holder identified on the signature page hereto (the “ Holder ”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below). WHEREAS, the Holder i…
Read attachment ↗